EP0644892A1 - Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine - Google Patents

Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine

Info

Publication number
EP0644892A1
EP0644892A1 EP93909587A EP93909587A EP0644892A1 EP 0644892 A1 EP0644892 A1 EP 0644892A1 EP 93909587 A EP93909587 A EP 93909587A EP 93909587 A EP93909587 A EP 93909587A EP 0644892 A1 EP0644892 A1 EP 0644892A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
substituents
unsaturated heterocycle
substituted
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93909587A
Other languages
German (de)
English (en)
Inventor
Dennis J. Hoover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP0644892A1 publication Critical patent/EP0644892A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composé de la formule (I) permettant de prévenir ou de traiter efficacement l'hypertension, l'insuffisance cardiaque, l'infarctus du myocarde, l'hypertrophie cardiaque et du ventricule gauche, les affections des artères coronaires comprenant l'infarctus du myocarde, l'hypertrophie vasculaire, ainsi que des lésions vasculaires résultant d'affections rénales diabétiques et non diabétiques, ainsi que des lésions vasculaires associées à l'angioplastie et l'aethéroma.
EP93909587A 1992-06-12 1993-04-23 Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine Withdrawn EP0644892A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89772392A 1992-06-12 1992-06-12
US897723 1992-06-12
PCT/US1993/003625 WO1993025574A1 (fr) 1992-06-12 1993-04-23 Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine

Publications (1)

Publication Number Publication Date
EP0644892A1 true EP0644892A1 (fr) 1995-03-29

Family

ID=25408314

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93909587A Withdrawn EP0644892A1 (fr) 1992-06-12 1993-04-23 Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine

Country Status (5)

Country Link
EP (1) EP0644892A1 (fr)
JP (1) JP2668003B2 (fr)
CA (1) CA2137832C (fr)
FI (1) FI932695A (fr)
WO (1) WO1993025574A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524267D0 (en) * 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
BR9712023A (pt) * 1996-09-10 1999-08-31 Thomae Gmbh Dr K Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
KR20000052775A (ko) * 1996-10-25 2000-08-25 가마쿠라 아키오 신규한 헤테로사이클릭 아미드 화합물 및 의약으로서의 그의 용도
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2321146A1 (fr) 1998-02-17 1999-08-19 Nippon Kayaku Kabushiki Kaisha Nouveau derive d'acetamide et son utilisation
CA2341195A1 (fr) * 1998-08-20 2000-03-02 Mitsunori Waki Compositions prophylactique ou therapeutique pour les troubles circulatoires oculaire
AU1414000A (en) * 1998-12-01 2000-06-19 Meiji Seika Kaisha Ltd. Sf2809-i, ii, iii, iv, v and vi substances exhibiting chymase-inhibiting activities
DE60034545T2 (de) 1999-11-01 2007-10-25 Asubio Pharma Co., Ltd. Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
CA2368382A1 (fr) 2000-02-22 2001-08-30 Suntory Limited Medicaments pour la prevention et le traitement des dermatites contenant des inhibiteurs de chymase en tant que principe actif
CN1366461A (zh) 2000-02-22 2002-08-28 三得利株式会社 含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物
CA2365606A1 (fr) 2000-02-22 2001-08-30 Suntory Limited Medicaments pour la prevention ou le traitement de differentes maladies impliquant une augmentation de chymase eosinophiles en tant que principe actif
WO2001083471A1 (fr) * 2000-05-02 2001-11-08 Meiji Seika Kaisha, Ltd. Nouveaux derives indoliques presentant des activites inhibitrices de chymase et leur procede de preparation
WO2002006280A2 (fr) * 2000-07-13 2002-01-24 Millennium Pharamaceuticals, Inc. Inhibiteurs du facteur xa
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US20060217421A1 (en) 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
SI2364309T1 (sl) 2008-12-10 2015-03-31 Achillion Pharmaceuticals, Inc. Novi 4-amino-4-oksobutanoil peptidi kot inhibitorji virusne replikacije
WO2014145600A1 (fr) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Polymorphes de sel de sodium d'ach-0142684, composition les comprenant, et leur procédé de fabrication
KR20160005686A (ko) 2013-03-15 2016-01-15 아칠리온 파르마세우티칼스 인코포레이티드 소바프레비르 다형체들 및 이의 제조 방법
EP3472151A4 (fr) 2016-06-21 2020-03-04 Orion Ophthalmology LLC Dérivés de prolinamide carbocycliques
AU2017282651B2 (en) 2016-06-21 2021-08-12 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ZA905737B (en) * 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
EP0587799B1 (fr) * 1991-05-23 1999-07-07 Merrell Pharmaceuticals Inc. Inhibiteurs de la cathepsine g et de l'elastase empechant la degradation du tissu conjonctif

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9325574A1 *

Also Published As

Publication number Publication date
WO1993025574A1 (fr) 1993-12-23
CA2137832C (fr) 2000-09-26
JPH07507069A (ja) 1995-08-03
FI932695A (fi) 1993-12-13
JP2668003B2 (ja) 1997-10-27
FI932695A0 (fi) 1993-06-11
CA2137832A1 (fr) 1993-12-23

Similar Documents

Publication Publication Date Title
CA2137832C (fr) Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain
US5714485A (en) Piperidine and hexahydropyridazine thrombin inhibitors
US6432921B2 (en) Thrombin inhibitors
US5496927A (en) Peptidase inhibitors
US5430023A (en) Tripeptide antithrombotic agents
AU2002314067B2 (en) Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
EP0956294B1 (fr) Inhibiteurs de la thrombine
EP0800528A1 (fr) Peptide et analogue peptidique agissant comme inhibiteurs de protease
CA2031684A1 (fr) Produits pharmaceutiques
US6218365B1 (en) Serine protease inhibitors
HUT61744A (en) Process for producing renin inhibiting alkylaminocarbonyl group-substituted heterocyclic compounds
DE4443390A1 (de) Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
CA2034315A1 (fr) Inhibateurs de la renine oralement actifs
US5140011A (en) Amino acid derivatives which have renin inhibiting activity
EP1049673A1 (fr) Amidines heterocycliques utilisees comme inhibiteurs de la kallicreine
US6265381B1 (en) Orally-active elastase inhibitors
EP0207680B1 (fr) Composés chimiques
CA2006839A1 (fr) Inhibiteurs de la renine contenant des amides a groupement dihydroxy en position c-terminale
US4503043A (en) Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids
JPS63218697A (ja) ジフルオルシクロスタチン含有ポリペプチド
CA2013475A1 (fr) Derives d'acides amines
RU2172321C2 (ru) Ингибиторы сериновых протеаз
JPH01110695A (ja) アミノ酸誘導体その製造方法及び血圧降下剤
MXPA98007090A (en) Inhibitors of serine prote
MXPA99001439A (en) Thrombin inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19960322

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971104